BX LAB TECHNICAL ARTICLE
What the Data Says About Stereodefined Phosphorothioate
The literature does not say stereopure is better. It says the pattern matters, and all-Rp fails in vivo.
Key takeaways
A 20-mer phosphorothioate is a mixture of roughly half a million stereoisomers.
Uniform Rp gaps match stereorandom activity in vitro but are metabolised quickly in vivo.
Building a designed Rp/Sp pattern needs both diastereomers of each monomer, not just one.
Start with the number
Every phosphorothioate linkage is a stereocentre. A 20-mer has 19 of them, which is 2¹⁹ — about half a million stereoisomers in what the vial calls one compound. Iwamoto and colleagues put it plainly in 2017: mixtures of that size persisted in antisense drugs because it had been feasible neither to separate the isomers nor to synthesise them cleanly. Mipomersen was approved as such a mixture. That is the problem stereocontrol exists to solve, and it is worth being precise about what "solved" turns out to mean.
The obvious answer is wrong
If one diastereomer were simply better, the job would be to make all-Rp or all-Sp and stop. Ionis tested that directly. Wan and colleagues built 31 gapmer ASOs with the chirality of every linkage in the 10-base gap defined, at 98% stereoselectivity per coupling, and measured Tm, nuclease stability, RNase H activation and activity both in vitro and in vivo. Gaps carrying nine or more Sp linkages were poorly active in cells. Uniform Rp gaps were active — about as active as the stereorandom parent, which is already a sobering result. Then the same all-Rp compound went into animals and was metabolised so quickly that activity collapsed. Their conclusion was that a mix of Rp and Sp is needed to balance activity against nuclease stability.
Why that changes what you buy
A designed Rp/Sp pattern is not built from a preferred monomer. It is built from both diastereomers of each monomer, placed deliberately along the sequence. Rp where RNase H needs it, Sp where the linkage has to survive a nuclease. That means a stereocontrolled campaign depends on having the (D)- and (L)- forms of the chiral auxiliary for every base you intend to modify — and being able to get them from the same source, at the same quality, at the same time. A supplier who stocks only the popular isomer cannot support the experiment that matters.
Two chemistries get you there
The established route is P(III): oxazaphospholidine monomers that set the configuration during coupling. Nukaga, Oka and Wada showed these run on an ordinary automated synthesiser alongside conventional phosphoramidites, producing PO/PS chimeras where each linkage type is placed on purpose. The newer route is P(V). Knouse and colleagues reported a reagent platform that installs the stereocentre from a phosphorus(V) starting point rather than P(III), which they applied to both antisense oligonucleotides and cyclic dinucleotides. The two approaches differ in monomer availability, cycle time and where the stereochemistry is decided; neither has made the other redundant.
Plan the standards before the campaign, not after
Stereochemical purity is a claim until it is measured, and it is measured against resolved diastereomers. Get the Rp and Sp reference standards for the linkage you care about before the synthesis, not when a reviewer asks. This is also the part of the problem that is easy to underestimate: separating and assigning diastereomers is the same difficulty that made stereorandom mixtures the default in the first place. A supplier who cannot make the standards generally cannot make the stereocontrolled material either — the two capabilities come from the same chemistry.
Where the field is now
Stereocontrol did not turn out to be a switch that makes an ASO better. It turned out to be another design variable, and one that interacts with the rest of the backbone. Kandasamy and colleagues, working on splice-switching oligonucleotides, combined stereopure phosphorothioate with phosphoryl guanidine linkages rather than treating chirality on its own. Read the literature that way: the question is not whether to go stereopure, but which positions need which configuration in your sequence, and whether you can obtain the monomers to test the answer.
Turn the product name into a decision-ready specification
A purchasing name is only the starting point for a research material. Build the specification around exact chemical identity, form and assay basis. Define how identity will be confirmed and distinguish chromatographic purity from assay, concentration or active-content measurements. Add the attributes that could alter use, such as water, residual solvent, counterion, residual metals, known related substances or storage sensitivity. Acceptance limits should reflect the intended function rather than copying every available analytical result into a specification. Where a method is critical, record the technique, column or detection principle and sample preparation assumptions. This gives chemistry, analytical and procurement teams one shared definition of the material and reduces the chance that a technically correct but operationally unsuitable lot enters the project.
Qualify the material in the workflow that matters
A CoA can establish lot results against an agreed specification, but it cannot by itself prove performance in the intended research workflow. Plan a small, controlled qualification using a representative substrate, sequence, enzyme, reaction or analytical method. Include a suitable reference or previously accepted lot when available, keep preparation conditions comparable and predefine the observations that will trigger acceptance or investigation. Useful endpoints can include conversion, coupling efficiency, impurity formation, recovery, transcript integrity, conjugation yield or downstream signal, depending on the material. Record both the chemical result and practical behavior such as dissolution time, foaming, color change, precipitation or instrument delivery. This separates a material-quality question from a process-compatibility question and creates evidence that can support later lot-to-lot comparison.
Review process and scale risks before increasing quantity
Scale changes can expose risks that are not visible in a small research batch. For a research material, review handling, purification, analysis and scale-up before committing to a larger campaign. Estimate concentration, heat and mass-transfer needs, hold times, mixing limits, filtration area and the stability window of intermediates or prepared solutions. Identify the operations that control impurity rejection rather than assuming reaction yield alone will predict an acceptable isolated product. Raw-material availability and variability should be included in the route review, especially when a protecting-group reagent, specialty precursor or purification medium has a long lead time. A staged plan—feasibility, confirmation batch and then larger manufacture—provides checkpoints for analytical comparability, safety review and yield reconciliation while there is still room to adjust the process.
Build an analytical package that answers buyer questions
The useful documentation package should connect identity, purity and intended use. At minimum, align the specification and lot-specific Certificate of Analysis; then identify which supporting data are appropriate for the chemistry, such as HPLC or UPLC, LC-MS, high-resolution MS, NMR, water, residual solvents or inorganic-ion analysis. Chromatograms and spectra are most helpful when the material form, sample preparation and acceptance logic are clear. For complex or highly polar materials, a single percentage may not describe all relevant attributes, so note whether the result represents area purity, assay, concentration or another basis. Change control should cover shifts in route, critical starting material, purification approach, analytical method or manufacturing site when those changes could affect comparability. This framework helps technical, QA and procurement reviewers reach the same conclusion from the same evidence.
Use a structured request to shorten technical review
A complete inquiry for a research material should include the structure or unambiguous identifier, desired form, target quantity, expected future scale, intended use, target date and required documentation. Add known constraints: sensitive functional groups, prohibited solvents, metal limits, water sensitivity, shipping temperature, packaging preference or compatibility with an established method. If the request supports a regulatory submission, state the development stage and the documents expected, but do not assume that research-use or non-GMP material carries a qualification it does not have. Ask the supplier to identify open assumptions in the quotation and to separate confirmed specification items from values that still require method development. The resulting technical exchange is more efficient, and the final quotation can be tied to a material definition that is meaningful to scientists, procurement and quality reviewers.
Build a fit-for-purpose request
Before sourcing or scale-up, align the exact structure, intended workflow, target purity and assay basis, required form, storage conditions, quantity, timeline and documentation. If a catalog item does not match those requirements, a related analog, impurity standard, reference material or research-use custom route can be reviewed.
References
Technical context is supported by the peer-reviewed literature below.
- Iwamoto et al. (2017) Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nature Biotechnology
- Wan et al. (2014) Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Research
- Nukaga, Oka & Wada (2016) Stereocontrolled solid-phase synthesis of PO/PS chimeric oligodeoxyribonucleotides using an oxazaphospholidine-phosphoramidite method. Journal of Organic Chemistry
- Knouse et al. (2018) Unlocking P(V): reagents for chiral phosphorothioate synthesis. Science
- Kandasamy et al. (2022) Control of backbone chemistry and chirality boost oligonucleotide splice switching activity. Nucleic Acids Research